ArticleNeurodegenerative disease management2013
Should we disclose amyloid imaging results to cognitively normal individuals?
Article in Neurodegenerative disease management, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 3 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Considerations regarding a diagnosis of Alzheimer's disease before dementia: a systematic review.Alzheimer's research & therapy · 2022Pooled it
- Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review.Alzheimer's research & therapy · 2018Pooled it
- Psychological, behavioral and social effects of disclosing Alzheimer's disease biomarkers to research participants: a systematic review.Alzheimer's research & therapy · 2016Pooled it
- Attitudes of Research Participants and the General Public Regarding Disclosure of Alzheimer Disease Research Results.JAMA neurology · 2015Trial
- Just Semantics? How Diagnostic Criteria Influence Physician-Patient Narratives in Alzheimer's Disease.Neuro-degenerative diseases · 2026Article
- Toxicity Concerns Associated with the Radiopharmaceuticals for the Diagnosis of Alzheimer's Disease.Central nervous system agents in medicinal chemistry · 2025Article
- Testing for Alzheimer Disease Biomarkers and Disclosing Results Across the Disease Continuum.Neurology · 2023Article
- US Adults' Likelihood to Participate in Dementia Prevention Drug Trials: Results from the National Poll on Healthy Aging.The journal of prevention of Alzheimer's disease · 2023Article
- Family members' perspectives on learning cognitively unimpaired older adults' amyloid-β PET scan results.Journal of the American Geriatrics Society · 2021Article
- The Framing of "Alzheimer's Disease": Differences Between Scientific and Lay Literature and Their Ethical Implications.The Gerontologist · 2021Article
- Article
- Added value of amyloid PET in individualized risk predictions for MCI patients.Alzheimer's & dementia (Amsterdam, Netherlands) · 2019Article
- Stakeholders' Views on Early Diagnosis for Alzheimer's Disease, Clinical Trial Participation and Amyloid PET Disclosure: A Focus Group Study.Journal of bioethical inquiry · 2019Article
- Research Use of Ecological Momentary Assessment for Adverse Event Monitoring Following Amyloid-β Results Disclosure.Journal of Alzheimer's disease : JAD · 2019Review
- Reactions to learning a "not elevated" amyloid PET result in a preclinical Alzheimer's disease trial.Alzheimer's research & therapy · 2018Article
- Association of Amyloid Positron Emission Tomography With Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort: The ABIDE Project.JAMA neurology · 2018Article
- From information to follow-up: Ethical recommendations to facilitate the disclosure of amyloid PET scan results in a research setting.Alzheimer's & dementia (New York, N. Y.) · 2018Review
- Review
- Study partners should be required in preclinical Alzheimer's disease trials.Alzheimer's research & therapy · 2017Review
- Safety of disclosing amyloid status in cognitively normal older adults.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Demonstration of brain accumulation of fibrillar amyloid beta protein via positron emission tomography (PET) with amyloid specific ligands may support the diagnosis of Alzheimer's disease (AD). There is increasing recognition of the potential use of amyloid imaging to detect
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.